T-E Meds, Inc., founded in 2022, was the second subsidiary of T-E Pharma Holding, focused on the development of antibody-derived drug candidates by the innovative antibody-drug conjugate (ADC) or antibody-radionuclide conjugate (ARC) platforms. These potential drugs are intended for the treatment of various lethal cancers, including multiple myeloma and pancreatic cancer.

Another affiliated company, the sister company of TE-Meds – Immunwork, Inc., was established in 2014. The innovative fatty acid bundle platform has been applied to develop the ultra-long-acting drug candidates for the treatment of critical endocrine diseases, such as diabetes, obesity, acromegaly and neuroendocrine tumors. Two promising candidates are in Phase I clinical trial now.  

Immunwork website: https://www.immunwork.com/